The metabolism of antihistamines and drug interactions: The role of cytochrome P450 enzymes

Clinical and Experimental Allergy, Supplement

Volumn 29, Issue 3, 1999, Pages 116-124

  Renwick, A G ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Cardiotoxicity; Cytochrome P450; Metabolism; Pharmacokinetics

Indexed keywords

ANTIHISTAMINIC AGENT; ASTEMIZOLE; CETIRIZINE; CIMETIDINE; CYTOCHROME P450; DIRITHROMYCIN; ERYTHROMYCIN; FEXOFENADINE; GLYCOPROTEIN P; HYDROXYZINE; ITRACONAZOLE; KETOCONAZOLE; LORATADINE; MACROLIDE; TERFENADINE; ZILEUTON;

ARTICLE; CARDIOTOXICITY; DRUG BIOAVAILABILITY; DRUG METABOLISM; HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL;

EID: 0032777032     PISSN: 09602178     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.1999.0290s3116.x     Document Type: Article

References (81)

1. Thummel KE, Kunze KL, Shen DD. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev 1997; 27:99-127.
2. 1 receptor antagonist therapy. Clin Pharmacokin 1991; 21:372-93.
3. Moller C, Andlin-Sobocki P, Blychert LO. Pharmacokinetics of astemizole in children. Rhinol 1992; 30 (Suppl.13):21-5.
4. Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarisation on the electrocardiogram. Clin Pharmacol Therap 1996; 59:383-8.
5. Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS. The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. Eur J Clin Pharmacol 1997; 52:311-5.
6. Yun CH, Okerholm RA, Guengerich FP. Oxidation of the antihistaminic drug terfenadine in human liver microsomes: Role of cytochrome P-450 3A (4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos 1993; 21:403-9.
7. Kolars JC, Lown KS, Schmiedlin-Ren P, et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994; 4:247-59.
8. Ling KHJ, Leeson GA, Burmaster SD, Hook RH, Reith MK, Cheng LK. Metabolism of terfenadine associated with CYP3A (4) activity in human hepatic microsomes. Drug Metab Dispos 1995; 23:631-6.
9. Yumibe N, Huie K, Chen KJ, Snow M, Clement RP, Cayen MN. Identification of human liver cytochrome P450 enzymes that metabolize the non-sedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem Pharmacol 1996; 51:165-72.
10. Roos PH, Mahnke A. Metabolite complex formation of orphenadrine with cytochrome P450. Involvement of CYP2C11 and CYP3A isozymes. Biochem Pharmacol 1996; 52:73-84.
11. Blychert E, Edgar B, Elmfeldt D, Hednor T. A population study of the pharmacokinetics of felodipine. Br J Clin Pharmacol 1991; 31:15-24.
12. Ahsan CH, Renwick AG, Waller DG, et al. The influences of dose and ethnic origins on the pharmacokinetics of nifedipine. Clin Pharmacol Ther 1993; 54:329-38.
13. Lown KS, Kolars JC, Thummel KE, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by erythromycin breath test. Drug Metab Disp 1994; 22:947-55.
14. Gan LSL, Thakker DR. Applications of the Caco-2 model in the design and development of orally active drugs: Elucidation of biochemical and physical barriers by the intestinal epithelium. Adv Drug Deliv Res 1997; 23:77-98.
15. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Res 1997; 27:161-70.
16. Hunter J, Hirst BH. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv Drug Deliv Res 1997; 25:129-57.
17. Herbert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Res 1997; 27:201-14.
18. Schuetz EG, Beck WT, Schuetz JD. Modulation and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996; 49:311-8.
19. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr 1) in interpatient variation in oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62:248-60.
20. Rabbaa L, Pautrey S, Colas-Linhart N, Carbon C, Farinotti R. Intestinal elimination of ofloxacin enantiomers in the rat: Evidence of a carrier-mediated process. Antimicrob Agents Chemother 1996; 40:2126-30.
21. Bendayan R. Renal drug transport: a review. Pharmacother 1996; 16:971-85.
22. Koh KK, Rim MS, Yoon J, Kim SS. Torsade de pointes induced by terfenadine in a patient with long QT syndrome. J Electrocardiol 1994; 27:343-6.
23. 1 antagonist promethazine in human liver microsomes. Pharmacogenetics 1996; 6:449-57.
24. Chan TYK. Terfenadine-induced torsade de pointes: Risk factors and mechanisms. J Pharm Technol 1997; 13:127-32.
25. Kamisako T, Adachi Y, Nakagawa H, Yamamoto T. Torsades de pointes associated with terfenadine in a case of liver cirrhosis and hepatocellular carcinoma. Intern Med 1995; 34:92-5.
26. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR. Torsades de pointes occurring in association with terfenadine use. J Am Med Assoc 1990; 264:2788-90.
27. Hey JA Del, -Prado M, Kreutner W, Egan RW. Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes. Arzneim Forsch Drug Res 1996; 46: 159-63.
28. 1-antihistamines in a guinea-pig model of arrhythmogenicity. Br J Pharmacol 1996; 119:187-8.
29. Hey JA, Del-Prado M, Sherwood J, Kreutner W, Egan RW. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. Arzneim Forsch Drug Res 1996; 46:153-8.
30. Vorperian VR, Zhou Z, Mohammad S, et al. Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. J Am College Cardiol 1996; 28:1556-61.
31. Horsmans Y, Desager JP, Hulhoven R, Harvengt C. Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease. J Clin Pharmacol 1993; 33:929-32.
32. Sale ME, Barbey JT, Woosley RL, et al. The electrocardiographic effects of cetirizine in normal subjects. Clin Pharmacol Ther 1994; 56:295-301.
33. Ohtani H, Kotaki H, Sawada Y, Iga T. A comparative pharmacokinetic-pharmacodynamic study of the electrocardiographic effects of epinastine and terfenadine in rats. J Pharm Pharmacol 1997; 49:458-62.
34. Woosley RL. Cardiac actions of antihistamines. Ann Rev Pharmacol Toxicol 1996; 36:233-52.
35. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences. J Am Med Assoc 1993; 269:1513-8.
36. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993; 45:191-3.
37. Honig PK, Wortham DC, Hull R, et al. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol 1993; 33:1201-6.
38. Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 1997; 61:410-5.
39. De-Wildt SN, Van-den-Anker JN, Romkes JH, et al. Loss of consciousness due to simultaneous use of terfenadine and itraconazole. Ned Tijdschr Geneeskd 1997; 141:1752-4.
40. Honig PK, Wortham DC, Zamahni K, et al. The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin Pharmacol Ther 1993; 53:630-6.
41. Lefebvre RA, Van-Peer A, Woestenborghs R. Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. Br J Clin Pharmacol 1997; 43:319-22.
42. Adusumalli VE, Wong KK, Kucharczyk N, Sofia RD. Pharmacokinetics of azelastine and its active metabolite, desmethylazelastine, in guinea pigs. Drug Metab Dispos 1992; 20:530-5.
43. Peter G, Romeis P, Borbe HO, Buker KM, Riethmuller-Winzen H. Tolerability and pharmacokinetics of single and multiple doses of azelastine hydrochloride in elderly volunteers. Arzneim Forsch Drug Res 1995; 45:576-81.
44. Gillum JG, Israel DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993; 25:450-82.
45. Ludden TM. Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet 1985; 10:63-79.
46. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992; 52:231-8.
47. Watkins VS, Polk RE, Stotka JL, Labrada L, Dion P. Drug interactions of macrolides: Emphasis on dirithromycin. Ann Pharmacother 1997; 31:349-56.
48. Honig PK, Wortham DC, Zamani K, Cantilena LR. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest 1994; 7:148-56.
49. Harris S, Hilligoss DM, Colangelo PM, Eller M, Okerholm R. Azithromycin and terfenadine: Lack of drug interaction. Clin Pharmacol Ther 1995; 58:310-5.
50. Brannan MD, Reidenberg P, Radwanski E, et al. Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations. Clin Pharmacol Therap 1995; 58:269-78.
51. Bachmann K, Sullivan TJ, Reesc JH, et al. A study of the interaction between dirithromycin and astemizole in healthy adults. Am J Ther 1997; 4:73-9.
52. Honig PK, Wortham DC, Zamani K, et al. Effect of concomitant administration of cimetidine and ranitidine on the pharmacokinetics and elctrocardiographic effects of terfenadine. Eur J Clin Pharmacol 1993; 45:41-6.
53. Renwick AG, Le Vie J, Challenor VF, et al. Factors affecting the pharmacokinetics of nifedipine. Eur J Clin Pharmacol 1987; 32:351-5.
54. 1-receptor antagonist ebastine to its active metabolite carebastine. Br J Clin Pharmacol 1993; 35:661-3.
55. 1-antagonists hydroxyzine and cetirizine in patients with chronic urticaria. J Allergy Clin Immunol 1995; 95:685-93.
56. Bailey DG, Spence JD, Munroz C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337:268-9.
57. Miniscalco A, Lundahl J, Regardh CG, Edgar B, Eriksson UG. Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. Pharmac Exp Ther 1992; 261:1195-9.
58. Bailey DG, Malcolm J, Arnold O, Munoz C, David-Spence J. Grapefruit juice-felodipine interaction. Mechanism, predictability and effect of naringin. Clin Pharmacol Ther 1993; 53:637-42.
59. Rashid J, McKinstry C, Renwick AG, Dirnhuber M, Waller DG, George CF. Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice. Br J Clin Pharmacol 1993; 36:460-3.
60. Edwards DJ, Bernier SM. Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juice. Life Sci 1996; 59:1025-30.
61. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents: Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997; 25: 1228-33.
62. Fukuda K, Ohta T, Oshima Y, et al. Specific CYP3A4 inhibitors in grapefruit juice: Furocoumarin dimers as components of drug interaction. Pharmacogenetics 1997; 7:391-6.
63. Fuhr W, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol 1993; 35:431-6.
64. Kang JH, Roh HK, Lee YS, et al. Effect of grapefruit juice on CYP1A2 dependent metabolism of caffeine in Koreans. J Korean Soc Clin Pharmacol Ther 1997; 5:26-34.
65. Fuhr U, Majer A, Keller A, et al. Lacking effect of grapefruit juice on theophylline pharmacokinetics. Int J Clin Pharmacol Ther 1995; 33:311-4.
66. Maish WA, Hampton EM, Whitsett TL, Shepard JD, Lovallo WR. Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics. Pharmacotherapy 1996; 16:1046-52.
67. Edwards DJ, Bellevue II, Woster PM. Identification of 6′,7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos 1996; 24: 1287-90.
68. Rau SE, Bend JR, Arnold JMO, et al. Grapefruit juice-terfenadine single-dose interaction: magnitude, mechanism and relevance. Clin Pharmacol Ther 1997; 61:401-9.
69. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration of grapefruit juice. Clin Pharmacol Therap 1995; 57:485-91.
70. Rashid TJ, Martin U, Clarke H, et al. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 1995; 40:51-8.
71. Awni WM, Cavanaugh JH, Leese P, et al. The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine. Eur J Clin Pharmacol 1997; 52:49-54.
72. Robinson DS, Roberts DL, Smith JM, et al. The safety profile of nefazodone. J Clin Psychiatry 1996; 57 (Suppl.2): 31-8.
73. Nemeroft CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome p450 system. Am J Psychiatry 1996; 153:311-20.
74. Li AP, Jurima-Romet M. Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug - drug interactions: Evaluation of model drugs terfenadine and rifampcin. Cell Biol Toxicol 1997; 13:365-74.
75. Von-Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright CE. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: Relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol 1996; 16:104-12.
76. Von-Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI. Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995; 29 (Suppl. 1): 33-44.
77. Jurima-Romet M, Crawford K, Cyr T, Inaba T. Terfenadine metabolism in human liver: In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 1994; 22:849-57.
78. Jurima-Romet M, Huang HS, Beck DJ, Li AP. Evaluation of drug interactions in intact hepatocytes: Inhibitors of terfenadine metabolism. Toxicol Vitro 1996; 10:655-63.
79. Kumar GN, Rodrigues AD, Buko AM, Denissen JF, Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277:423-31.
80. Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: Potential contribution to high first-pass metabolism. Drug Metab Dispos 1997; 25:256-66.
81. Ament PW, Paterson A. Drug interactions with the nonsedating antihistamines. Am Fam Phys 1997; 56:223-30.